Kaysersberg Pharmaceuticals
FDA inspection history in Kaysersberg-Vignoble, France, 2016 to 2023
- 2
- Form 483s
Every document, by year
- Form 483
2016: one Form 483; 2023: one Form 483.
The story so far
Built from the dates and citations on the documents themselves.
- 2016One Form 483.
- 2016The longest 483 on file: 8 observations over 4 pages.
- 2023One Form 483, at Kaysersberg-Vignoble, France.
Cited most
Across all Kaysersberg Pharmaceuticals observations on file
- 21 CFR 211.68Automatic, mechanical, and electronic equipment2
- 21 CFR 211.100(b)Written procedures; deviations1
- 21 CFR 211.110(a)Sampling and testing of in-process materials and drug products1
- 21 CFR 211.160(b)General requirements1
- 21 CFR 211.165Testing and release for distribution1
The complete Kaysersberg Pharmaceuticals file.
All 2 documents as original PDFs, in one order. For supplier audits, diligence and inspection prep.
The price of the documents, added to your cart together
Sites
Kaysersberg-Vignoble, France
One Form 483 · 2023 · 2 observations
Latest: Form 483, Jul 7, 2023 →
Also: one document not tied to a site.
Documents
2 on file, newest first| Date | Document | Location | Observations | Price |
|---|---|---|---|---|
| 2023-07-07 | 483 Form 483 | Kaysersberg-Vignoble, France | 2 | $99 |
| 2016-07-19 | 483 Form 483 | — | 8 | $99 |
Investigators on these documents
FEI number 3002806288 · most recent document Jul 7, 2023
About Kaysersberg Pharmaceuticals
How many FDA Form 483s has Kaysersberg Pharmaceuticals received?
FDA Intel has 2 Form 483s on file for Kaysersberg Pharmaceuticals; the most recent is dated Jul 7, 2023.
When was Kaysersberg Pharmaceuticals last inspected by FDA?
The most recent FDA inspection document on file for Kaysersberg Pharmaceuticals is a Form 483 dated Jul 7, 2023, for the site in Kaysersberg-Vignoble, France.
What did FDA cite at Kaysersberg Pharmaceuticals?
The regulations cited most in the observations on file for Kaysersberg Pharmaceuticals are 21 CFR 211.68 (Automatic, mechanical, and electronic equipment), 2 times; 21 CFR 211.100(b) (Written procedures; deviations), 1 time; 21 CFR 211.110(a) (Sampling and testing of in-process materials and drug products), 1 time.